Clinical features of Proteus mirabilis pneumonia.
Okimoto N, Hayashi T, Ishiga M, Nanba F, Kishimoto M, Yagi S, Kurihara T, Asaoka N, Tamada S.
J Infect Chemother. 2010 Oct;16(5):364-6. doi: 10.1007/s10156-010-0059-3. Epub 2010 May 26.
Pneumonia due to Proteus mirabilis treated with penicillin and streptomycin.
SNORF LD, SHEPANEK L, et al.
J Am Med Assoc. 1947 Sep 27;135(4):222. doi: 10.1001/jama.1947.62890040002006a.
Hospital-acquired pneumonia.
McHenry MC, Alfidi RJ, Deodhar SD, Braun WE, Popowniak KL.
Med Clin North Am. 1974 May;58(3):565-80. doi: 10.1016/s0025-7125(16)32144-7.
Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.
Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, Yamaguchi A, Kanamori M, Kamada N, Hattori M, Ashida H, Sakamoto M, Atarashi K, Narushima S, Yoshimura A, Honda K, Sato T, Kanai T.
Nat Microbiol. 2019 Mar;4(3):492-503. doi: 10.1038/s41564-018-0333-1. Epub 2019 Jan 14.
Purple urine.
Fernández de Orueta L, Esteban Fernández J, Pérez Caballero G, Melero Bermejo JA, Regajo Gallego R, Martínez Carrilero J.
Nefrologia. 2011;31(4):489-90. doi: 10.3265/Nefrologia.pre2011.May.10868.
Inhibitor-resistant beta-lactamases.
Nicolas-Chanoine MH.
J Antimicrob Chemother. 1997 Jul;40(1):1-3. doi: 10.1093/jac/40.1.1.
Pneumonia following tracheostomy.
Rogers LA, Osterhout S.
Am Surg. 1970 Jan;36(1):39-46.
Proteus mirabilis and Klebsiella pneumoniae as pathogens capable of causing co-infections and exhibiting similarities in their virulence factors.
Palusiak A.
Front Cell Infect Microbiol. 2022 Oct 20;12:991657. doi: 10.3389/fcimb.2022.991657. eCollection 2022.
[KITASAMYCIN].
DESVIGNES A.
Ann Pharm Fr. 1963 Jul-Aug;21:569-77.
BACTERIAL NUCLEOTIDASES.
KOHN J, REIS JL.
J Bacteriol. 1963 Oct;86(4):713-6. doi: 10.1128/jb.86.4.713-716.1963.
